ALS Therapy Development Institute and California Stem Cell, Inc. Announce Long-Term Scientific Collaboration
ALS Therapy Development Institute and California Stem Cell, Inc announced recently a new collaboration aimed at advancing any potential application of stem cells in treating ALS – amyotrophic lateral sclerosis, commonly known as Lou Gehrig’s diseases.
Genentech Forms Special Committee of Independent Directors to Review Roche Proposal
Genentech, Inc. announced recently that it has formed a special committee of its Board of Directors, composed of the company’s three independent directors, to assess the proposal from Roche to acquire all of the outstanding shares of Genentech stock not owned by Roche at a price of $89.00 in cash per share.
Invitrogen Licenses Stem Cell Line from Buck Institute
Invitrogen Corporation has licensed an engineered stem cell line from the Buck Institute for Age Research. The stem cell line is used in the study of neural cells in neurodegenerative disease.
WaferGen, Inc. Signs Exclusive Distribution Agreements for SmartSlide(TM) Micro-Incubation System in Switzerland, Taiwan and the Nordic Region
WaferGen Biosystems, Inc. recently announced the signing of exclusive distribution agreements for the company’s SmartSlide Micro-Incubation System with Bucher Biotec AG in Switzerland, Unimed Healthcare Inc. in Taiwan and AH diagnostics AS in the Nordic region.
Nucleonics Inc. Seeks Buyers For RNAi Assets
Nucleonics is seeking a buyer for its assets after being unable to raise additional financing from private investors.
Building the Bionic Body
UNSW’s Faculty of Engineering has launched a world-class research facility focused on the development of a new generation of implantable bionic devices for the human body.
New Venture Capitalist Fund Aims for Dozen Stem Cell Firms
A $225 million venture fund – the first exclusively aimed at emerging stem cell companies – looks to line up its lead investors by the end of the year, possibly by the end of September.
Osiris Therapeutics Appoints Chief Financial Officer
Osiris Therapeutics, Inc. announced recently the appointment of Richard W. Hunt as Chief Financial Officer effective July 23, 2008.
CEO of The Australian Stem Cell Centre Replaced Over Conflicting Views
The Australian Stem Cell Centre recently announced the departure of the Chief Executive Officer, Professor Stephen Livesey.
The Esteemed Dr. Brian Annex Accepts Pluristem’s Invitation to Join its Scientific Advisory Board
Pluristem Therapeutics Inc. announced recently that Brian H. Annex, MD has accepted an appointment to the Company’s Scientific Advisory Board.